Tewane Pharma: what changed
Two fiscal years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
Tewane Pharma
Largest movements
- Current investments +€33,572
up €33,572 (+169.8%), from €19,766 to €53,338
- Cash +€10,767
up €10,767 (+20.0%), from €53,808 to €64,575
mainly Net result for the year (+€41,836) and Other debts (+€19,772)
- Receivables within one year -€6,068
down €6,068 (-24.8%), from €24,473 to €18,405
- Tangible fixed assets -€2,629
down €2,629 (-20.8%), from €12,628 to €9,999
of which Land and buildings: -€2,578
- Profit (loss) carried forward +€23,718
up €23,718 (+31.5%), from €75,338 to €99,056
- Other debts +€19,772
up €19,772 (+950.1%), from €2,081 to €21,853
- Trade debts -€7,557
down €7,557 (-92.5%), from €8,169 to €612
- Tax, wage and social debts -€1,906
down €1,906 (-7.2%), from €26,464 to €24,558
of which Remuneration and social security: -€5,000
- Gross operating margin +€9,390
up €9,390 (+18.4%), from €51,091 to €60,481
- Financial charges +€1,049
up €1,049 (+47.4%), from €2,212 to €3,261
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Cash bridge derived
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €115,095 | €149,853 | +€34,758 | +30.2% |
| Fixed assets | 21/28 | €12,628 | €9,999 | -€2,629 | -20.8% |
| Tangible fixed assets | 22/27 | €12,628 | €9,999 | -€2,629 | -20.8% |
| Land and buildings | 22 | €12,577 | €9,999 | -€2,578 | -20.5% |
| Plant, machinery and equipment | 23 | €51 | - | -€51 | |
| Current assets | 29/58 | €102,467 | €139,854 | +€37,387 | +36.5% |
| Amounts receivable within one year | 40/41 | €24,473 | €18,405 | -€6,068 | -24.8% |
| Trade receivables | 40 | €24,473 | €18,405 | -€6,068 | -24.8% |
| Current investments | 50/53 | €19,766 | €53,338 | +€33,572 | +169.8% |
| Cash at bank and in hand | 54/58 | €53,808 | €64,575 | +€10,767 | +20.0% |
| Deferred charges and accrued income | 490/1 | €4,420 | €3,536 | -€884 | -20.0% |
| Total equity and liabilities | 10/49 | €115,095 | €149,853 | +€34,758 | +30.2% |
| Equity | 10/15 | €78,138 | €101,856 | +€23,718 | +30.4% |
| Contributions | 10/11 | €2,800 | €2,800 | = | 0.0% |
| Profit (loss) carried forward | 14 | €75,338 | €99,056 | +€23,718 | +31.5% |
| Amounts payable | 17/49 | €36,957 | €47,997 | +€11,040 | +29.9% |
| Amounts payable within one year | 42/48 | €36,957 | €47,997 | +€11,040 | +29.9% |
| Current portion of amounts payable after more than one year | 42 | €243 | €974 | +€731 | +300.8% |
| Trade debts | 44 | €8,169 | €612 | -€7,557 | -92.5% |
| Suppliers | 440/4 | €8,169 | €612 | -€7,557 | -92.5% |
| Taxes, remuneration and social security | 45 | €26,464 | €24,558 | -€1,906 | -7.2% |
| Taxes | 450/3 | €21,464 | €24,558 | +€3,094 | +14.4% |
| Remuneration and social security | 454/9 | €5,000 | - | -€5,000 | |
| Other amounts payable | 47/48 | €2,081 | €21,853 | +€19,772 | +950.1% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €2,880 | €2,630 | -€250 | -8.7% |
| Other operating charges | 640/8 | €685 | €400 | -€285 | -41.6% |
| Gross operating margin | 9900 | €51,091 | €60,481 | +€9,390 | +18.4% |
| Operating profit (loss) | 9901 | €47,526 | €57,451 | +€9,925 | +20.9% |
| Financial income | 75/76B | - | €115 | +€115 | |
| Recurring financial income | 75 | - | €115 | +€115 | |
| Financial charges | 65/66B | €2,212 | €3,261 | +€1,049 | +47.4% |
| Recurring financial charges | 65 | €2,212 | €3,261 | +€1,049 | +47.4% |
| Profit (loss) for the period before taxes | 9903 | €45,314 | €54,305 | +€8,991 | +19.8% |
| Income taxes | 67/77 | €12,550 | €12,469 | -€81 | -0.6% |
| Profit (loss) for the period | 9904 | €32,764 | €41,836 | +€9,072 | +27.7% |
| Profit (loss) for the period to be appropriated | 9905 | €32,764 | €41,836 | +€9,072 | +27.7% |
Source: filed annual accounts (NBB), fiscal years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 5 October 2026 via checked.be.